Current studies have on the identification of novel antigens expressed in melanoma and renal cancers as well as the characterization of T cells that recognize epitopes of previously described antigens. In a recent study, a novel gene has been identified that encodes an antigen recognized by a T cell clone that was derived from a population of renal cancer reactive TIL. Ongoing studies to extend current immunotherapies to additional patients have also involved the analysis of responses directed against multiple peptide epitopes derived from gp100 and tyrosinase. Additional studies have involved the analysis of responses directed against antigens that are expressed in melanoma as well as a variety of highly prevalent malignancies such as breast and prostate cancer. Fur these studies, sequencing reactions have been carried out using BigDye Terminator Cycle Sequencing Kits and were analyzed on an Applied Biosystems 3100-Avant Genetic Analyzer that represents an integral part of the Surgery Branch DNA Sequencing Core. The FACS Core Facility is currently being utilized for the analysis of T cell populations that are administered to patients as a part of the analysis of ongoing clinical cancer adoptive immunotherapy trials. In addition, the FACS Core is utilized on a daily basis for the analysis of the results of experiments to analyze the results of in vitro experiments to examine factors that influence the phenotype and function of tumor reactive T cells as well as to carry out the separation of cells based upon their expression of cell surface markers. The FACS Core consists of four Becton/Dickinson flow cytometers, a FACSCalibur, two FACSCantos and a FACSARIA cell sorter.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC010948-03
Application #
8158341
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2010
Total Cost
$1,475,423
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Zacharakis, Nikolaos; Chinnasamy, Harshini; Black, Mary et al. (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24:724-730
Deniger, Drew C; Pasetto, Anna; Robbins, Paul F et al. (2018) T-cell Responses to TP53 ""Hotspot"" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res 24:5562-5573
Lu, Yong-Chen; Zheng, Zhili; Robbins, Paul F et al. (2018) An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. Mol Ther 26:379-389
Parkhurst, Maria; Gros, Alena; Pasetto, Anna et al. (2017) Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. Clin Cancer Res 23:2491-2505
Rosenberg, Steven A; Tran, Eric; Robbins, Paul F (2017) T-Cell Transfer Therapy Targeting Mutant KRAS. N Engl J Med 376:e11
Robbins, Paul F (2017) Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. Cancer J 23:138-143
Lu, Yong-Chen; Parker, Linda L; Lu, Tangying et al. (2017) Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol 35:3322-3329
Stevanovi?, Sanja; Pasetto, Anna; Helman, Sarah R et al. (2017) Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356:200-205
Assadipour, Yasmine; Zacharakis, Nikolaos; Crystal, Jessica S et al. (2017) Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:4347-4353
Tran, Eric; Robbins, Paul F; Rosenberg, Steven A (2017) 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18:255-262

Showing the most recent 10 out of 30 publications